Skip to main content
Top
Published in: Medical Oncology 4/2014

01-04-2014 | Original Paper

Evaluation of histidine-rich glycoprotein tissue RNA and serum protein as novel markers for breast cancer

Authors: Marwa Matboli, Sanaa Eissa, Hebatallah Said

Published in: Medical Oncology | Issue 4/2014

Login to get access

Abstract

Advances in the field of breast cancer (BC) biomarkers discovery facilitate diagnosis and treatment of BC in its pre-invasive state. While the genetic tissue markers are making significant advances in understanding the molecular basis of BC, serum has long been considered a rich source for biomarkers. So, integrated genomic and proteomic strategies play a huge role in the analytical validation of BC biomarkers and represent a true milestone in the areas of diagnostics and personalized medicine. This study included 60 cases (BC), 30 patients with fibroadenoma and 30 healthy women. Histidine-rich glycoprotein RNA (HRG) tissue expression was analyzed through gene expression-based outcome for breast cancer online algorithm (GOBO) bioinformatic analysis. To confirm our informatics analysis, HRG RNA was detected in breast tissue samples by RT-PCR, and HRG serum protein was estimated by ELISA. GOBO analysis revealed increased HRG RNA expression in all subtypes of BC with relative higher expression in basal subtype and grade 2. We confirmed these findings by HRG tissue RNA with 71.7 % sensitivity and 93.3 % specificity. HRG serum protein was 86.7 % sensitivity and 80 % specificity. HRG tissue RNA and serum protein could be considered as promising novel markers for prediction of BC prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide: IARC cancer base no. 10. Lyon: International Agency for Research on Cancer; 2012. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide: IARC cancer base no. 10. Lyon: International Agency for Research on Cancer; 2012.
2.
go back to reference Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. Int J Proteomics. 2011;2011:343582. Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. Int J Proteomics. 2011;2011:343582.
3.
go back to reference Cecchini RS, Costantino JP, Cauley JA, Cronin WM. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res. 2012;5(4):583–92.CrossRef Cecchini RS, Costantino JP, Cauley JA, Cronin WM. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res. 2012;5(4):583–92.CrossRef
5.
go back to reference Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747–52.PubMedCrossRef Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747–52.PubMedCrossRef
6.
go back to reference Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Presented at: 34th annual meeting of the American Society of Clinical Oncology; May 16–19, 1998. Los Angeles, CA. Abstract 377. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Presented at: 34th annual meeting of the American Society of Clinical Oncology; May 16–19, 1998. Los Angeles, CA. Abstract 377.
7.
go back to reference Herceptin [prescribing information]. South San Francisco, CA: Genentech, Inc; 2010. Herceptin [prescribing information]. South San Francisco, CA: Genentech, Inc; 2010.
8.
go back to reference Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. 2009;208(5):970–8.PubMedCrossRef Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. 2009;208(5):970–8.PubMedCrossRef
9.
go back to reference Thulin A. Role of histidine-rich glycoprotein in angiogenesis and tumor growth. Acta Universtatis Upsaliensis. Digital Comprehensive summaries of Uppsala Dissertation from faculty of medicine 505.63 pp. Uppsala; 2009. ISBN-978-91-554-7674-8. Thulin A. Role of histidine-rich glycoprotein in angiogenesis and tumor growth. Acta Universtatis Upsaliensis. Digital Comprehensive summaries of Uppsala Dissertation from faculty of medicine 505.63 pp. Uppsala; 2009. ISBN-978-91-554-7674-8.
10.
go back to reference Jain S, Zuka M, Liu J, et al. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci USA. 2010;104(21):9024–8.CrossRef Jain S, Zuka M, Liu J, et al. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci USA. 2010;104(21):9024–8.CrossRef
11.
go back to reference Carey LA. Molecular intrinsic subtypes of breast cancer. In Hayes DF, Dizon DS, editors. Up to date. Waltham, MA: Up To Date; 2012. Carey LA. Molecular intrinsic subtypes of breast cancer. In Hayes DF, Dizon DS, editors. Up to date. Waltham, MA: Up To Date; 2012.
12.
go back to reference Pinder SE, Elston CW, Ellis IO. In Invasive carcinoma: usual histological types. 3rd ed. In: Elston CW, Ellis IO, editors. The breast. Edinburgh: Churchill Livingstone; 1998. p. 283–337. Pinder SE, Elston CW, Ellis IO. In Invasive carcinoma: usual histological types. 3rd ed. In: Elston CW, Ellis IO, editors. The breast. Edinburgh: Churchill Livingstone; 1998. p. 283–337.
13.
go back to reference Sobin L, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. Hoboken, NJ: Wiley; 2009. Sobin L, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. Hoboken, NJ: Wiley; 2009.
14.
go back to reference World Health Organization. International histological classification of tumours. 2nd ed. Geneva: World Health Organization, 1969–1981. Berlin: Springer; 1988. Present. World Health Organization. International histological classification of tumours. 2nd ed. Geneva: World Health Organization, 1969–1981. Berlin: Springer; 1988. Present.
15.
go back to reference Hummon AB, Lim SR, Difilippantonio MJ, Ried T. Isolation and solubilization of proteins after TRIzol® extraction of RNA and DNA from patient material following prolonged storage. Biotech J. 2007;42:467–72.CrossRef Hummon AB, Lim SR, Difilippantonio MJ, Ried T. Isolation and solubilization of proteins after TRIzol® extraction of RNA and DNA from patient material following prolonged storage. Biotech J. 2007;42:467–72.CrossRef
16.
go back to reference Koide T, Foster D, Yoshitake S, Davie EW. Amino acid sequence of human histidine rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochem J. 1986;25:2220–5.CrossRef Koide T, Foster D, Yoshitake S, Davie EW. Amino acid sequence of human histidine rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochem J. 1986;25:2220–5.CrossRef
17.
go back to reference Sabbatini ARM, Battolla MB, Martini PE, Ranieri-Raggi DM, Moir AJG, Raggi A. Evidence that muscle cells do not express the histidine-rich glycoprotein associated with AMP deaminase but can internalise the plasma protein. Eur J Histochem. 2011;55(1):e6. doi:10.4081/ejh.2011.e6.PubMedCentralPubMed Sabbatini ARM, Battolla MB, Martini PE, Ranieri-Raggi DM, Moir AJG, Raggi A. Evidence that muscle cells do not express the histidine-rich glycoprotein associated with AMP deaminase but can internalise the plasma protein. Eur J Histochem. 2011;55(1):e6. doi:10.​4081/​ejh.​2011.​e6.PubMedCentralPubMed
18.
go back to reference Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of breast cancer. JAMA J. 2001;285(3):324–8.CrossRef Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of breast cancer. JAMA J. 2001;285(3):324–8.CrossRef
19.
go back to reference Zweig MH, Campbell G. Receiver operating characteristic (ROC) Plots, a fundamental evaluation tool in clinical medicine. Clin Chem J. 1993;39(4):561–77. Zweig MH, Campbell G. Receiver operating characteristic (ROC) Plots, a fundamental evaluation tool in clinical medicine. Clin Chem J. 1993;39(4):561–77.
20.
go back to reference Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS One J. 2011;6:e17911.CrossRef Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS One J. 2011;6:e17911.CrossRef
21.
go back to reference Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nat J. 2000;406:747–52.CrossRef Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nat J. 2000;406:747–52.CrossRef
22.
go back to reference Eissa S, Swellam M, Ismail M, Hamdy M, Mokhtar N. Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients. IUBMB Life J. 2004;56(8):483–90.CrossRef Eissa S, Swellam M, Ismail M, Hamdy M, Mokhtar N. Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients. IUBMB Life J. 2004;56(8):483–90.CrossRef
23.
go back to reference Thulin A, Ringvall M, Dimberg A, et al. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein. Mol Cancer Res J. 2009;7(11):1792–802.CrossRef Thulin A, Ringvall M, Dimberg A, et al. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein. Mol Cancer Res J. 2009;7(11):1792–802.CrossRef
24.
go back to reference Klenotic PA, Huang P, Palomo J. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol. 2010;176(4):2039–50.PubMedCentralPubMedCrossRef Klenotic PA, Huang P, Palomo J. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol. 2010;176(4):2039–50.PubMedCentralPubMedCrossRef
25.
go back to reference Saigo K, Yoshida A, Sugano W, Ryo R, Yamaguchi N. Histidine-rich glycoprotein in blood during inflammation, surgical operation or hemodialysis. Rinsho Ketsueki. 1990;31(12):1914–9.PubMed Saigo K, Yoshida A, Sugano W, Ryo R, Yamaguchi N. Histidine-rich glycoprotein in blood during inflammation, surgical operation or hemodialysis. Rinsho Ketsueki. 1990;31(12):1914–9.PubMed
26.
go back to reference Menga R, Gormleya M, Vadiraja B, Rosenbergc BA, Quonga AA. Low abundance protein enrichment for discovery of candidate plasma protein biomarkers for early detection of breast cancer. J Proteomics. 2011;1(75):366–74.CrossRef Menga R, Gormleya M, Vadiraja B, Rosenbergc BA, Quonga AA. Low abundance protein enrichment for discovery of candidate plasma protein biomarkers for early detection of breast cancer. J Proteomics. 2011;1(75):366–74.CrossRef
27.
go back to reference Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol J. 2006;7:910–8.CrossRef Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol J. 2006;7:910–8.CrossRef
28.
go back to reference DeMaat MPM, Kameling SWA, Kluft C. The sensitivity and specificity of some clotting rate and immunological fibrinogen assays for high, low and low molecular weight forms of fibrinogen. In: DeMaat MPM, editor. Regulation and modulation of the plasma fibrinogen level. Rotterdam: University of Rotterdam. Thesis; 1995. pp. 47–59. DeMaat MPM, Kameling SWA, Kluft C. The sensitivity and specificity of some clotting rate and immunological fibrinogen assays for high, low and low molecular weight forms of fibrinogen. In: DeMaat MPM, editor. Regulation and modulation of the plasma fibrinogen level. Rotterdam: University of Rotterdam. Thesis; 1995. pp. 47–59.
29.
go back to reference Rohleder N, Wolf JM, Piel M, Kirschbaum C. Impact of oral contraceptive use on glucocorticoid sensitivity of pro-inflammatory cytokine production after psychosocial stress. Psychoneuroendocrinology. 2003;28(3):261–73.PubMedCrossRef Rohleder N, Wolf JM, Piel M, Kirschbaum C. Impact of oral contraceptive use on glucocorticoid sensitivity of pro-inflammatory cytokine production after psychosocial stress. Psychoneuroendocrinology. 2003;28(3):261–73.PubMedCrossRef
30.
go back to reference Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337–42.PubMedCrossRef Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337–42.PubMedCrossRef
31.
go back to reference Shebl F, Pinto LA, Garcia-Pineres A, Lempicki R, Williams M, Harro C, Hildesheim A. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prev. 2010;19(4):978–81.PubMedCentralPubMedCrossRef Shebl F, Pinto LA, Garcia-Pineres A, Lempicki R, Williams M, Harro C, Hildesheim A. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prev. 2010;19(4):978–81.PubMedCentralPubMedCrossRef
Metadata
Title
Evaluation of histidine-rich glycoprotein tissue RNA and serum protein as novel markers for breast cancer
Authors
Marwa Matboli
Sanaa Eissa
Hebatallah Said
Publication date
01-04-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0897-4

Other articles of this Issue 4/2014

Medical Oncology 4/2014 Go to the issue